Hookipa Biotech AG announced the closure of its latest Series B financing round, where the company was able to raise EUR20 million. The round was led by existing investors namely Sofinnova Partners and Forbion Capital Partners and was joined by three new investors namely Boehringer Ingelheim Venture Fund, BioMedPartners and Takeda Ventures.

According to Hookipa Biotech AG CEO Dr. Katherine Cohen, "We made very substantial progress in the last two years and are delighted to have the support of a highly experienced syndicate of venture investors. I would like to thank our initial investors for their strong confidence in Hookipa and I look forward to working with our new investors as we enter in to the exciting next stage of development."

Hookipa developed the Vaxwave viral vector platform which has the capacity to stimulate antibody ad CD8+ T cell immunity. The lead product candidate based on this platform, HB101, is a vaccine against the dreaded cytomegalovirus. It is now in advanced pre-clinical and developmental testing stage. The funding would be utilized to further HB101 into Phase 1 clincial testing and further industrialize Vaxwave technology, for both partnering and for a robust supply chain in the area of infectious disease control and cancer management.